Targeted Protein Degradation– tag –
-
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
Pfizer and Arvinas’ Veppanu (vepdegestrant) Gains FDA Approval, Revolutionizing ESR1-Mutated Advanced Breast Cancer as First PROTAC
DCAT Value Chain Insights USA Overview In 2026, Pfizer and Arvinas' Veppanu (vepdegestrant) received FDA approval for advanced breast cancer with ESR1 mutations, becoming the first FDA-approved PROTAC. This drug offers a groundbreaking o... -
Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development
MarinBio USA Overview MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technol... -
Nurix Therapeutics’ Bexobrutideg Shows 83% ORR and 22.1 Months PFS in Relapsed/Refractory CLL/SLL Phase 1 Study
Nurix Therapeutics USA Overview Nurix Therapeutics reported updated clinical data from its NX-5948-301 Phase 1a/1b study, showing durable responses and a favorable tolerability profile for bexobrutideg in relapsed/refractory CLL/SLL pati... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
BMS Molecular Glue Mezigdomide Combination Therapy Transforms Oncology: Achieves 52% Reduction in Progression or Death Risk in Phase 3 Multiple Myeloma Trial
PMLiVE Unknown Overview Targeted protein degraders (TPDs), specifically PROTACs and molecular glues, are rapidly advancing in oncology. At ASCO, Bristol Myers Squibb (BMS) announced Phase 3 results showing their molecular glue, Mezigdomi... -
BMS Reveals Promising Clinical Data for Next-Gen Blood Cancer Therapy Mezigdomide
BioPharma Dive USA Overview Bristol Myers Squibb (BMS) unveiled promising new clinical data for mezigdomide, its next-generation blood cancer therapy. This drug is one of two key protein degradation inducers BMS expects to succeed its mu... -
Arvinas Accelerates Clinical Development of ARV-027 for Kennedy’s Disease, Targeting Mutant Androgen Receptor Degradation with PROTAC
Kennedy's Disease Association USA Overview Arvinas is steadily advancing the clinical development of ARV-027, an investigational PROTAC degrader for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy, SBMA). ARV-027 is designed to sel... -
Protai Introduces Structural-Proteomics-Guided AI ‘AIMS-Fold’ to Revolutionize Induced Proximity Drug Design
BioSpace USA Overview Protai announced two preprints introducing AIMS-Fold, a structural-proteomics-guided generative AI framework for protein complex modeling, specifically for induced proximity therapeutics like PROTACs and molecular g...
